Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blinded, placebo-controlled, investigator-initiated study of ACTEMRA (Tocilizumab) in adult onset Still's disease patients.

Trial Profile

Randomized, double-blinded, placebo-controlled, investigator-initiated study of ACTEMRA (Tocilizumab) in adult onset Still's disease patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Adult-onset Still's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 May 2019 According to the Chugai Pharmaceutical media release, this study wa sconducted at eight sites and led by Keio University Hospital.
    • 22 May 2019 According to the Chugai Pharmaceutical media release, the company has obtained regulatory approval for the humanized anti-human IL-6 receptor monoclonal antibody, ACTEMRA intravenous infusion 80 mg, 200 mg, and 400 mg for an additional indication of adult onset Still's disease from the Japanese Ministry of Health, Labour and Welfare, based on the data from this study.
    • 05 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top